Gyros Protein Technologies


Extended sensitivity of microfluidic immunoassays for pharmacokinetic (PK) and biomarker analysis


The use of ligand-binding assays in biotherapeutic development is a mainstay of analytical groups in biopharma companies. Since its introduction, the compact disk (CD) based, nanoliter-scale Gyrolab® microfluidic immunoassay platform has been widely accepted as an essential analytical technology due to its time-saving, automated, and robust performance. The success of the assay format centers around the microfluidic CD labware where the immunoassay takes place. Recently, the Gyrolab Bioaffy™ 4000 CD has been introduced to increase assay sensitivity 2- to 6-fold beyond the current 6-log dynamic range. In this poster, we present data pharmacokinetic (PK) and biomarker analysis down to low pg/mL levels with the Gyrolab Bioaffy 4000 CD demonstrating the sensitivity expansion of Gyrolab immunoassays facilitated with the new CD labware.

If you have problems downloading the poster, please contact